Divalproex sodium (Depakote) vs Divalproex sodium (Depakote ER)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Bipolar Disorder

Shared mechanism: GABAergic neurotransmission · full Bipolar Disorder pipeline

Divalproex sodium (Depakote)

Marketed by AbbVie

Approved in Bipolar Disordersmall molecule
Partial signal

NCT00194129 · Phase 3 · completed

This 6-month, randomized, double-blind trial enrolled patients with rapid-cycling bipolar disorder and substance abuse who had stabilized on lithium plus divalproex, and randomized 31 of them to continue both drugs or to switch divalproex to placebo. The primary outcome was time to a new mood episode. The median time was 17.8 weeks with the combination vs 15.9 weeks with lithium alone, a difference the paper reports as not significant, so the primary was missed. The sample was small. Source: the peer-reviewed paper (Kemp et al., J Clin Psychiatry 2009).

Reported efficacy

Time to Treatment for Emerging Symptoms of a Mood Relapse (Up to 6 months): Median time to a new mood episode over 6 months: 17.8 weeks with lithium plus divalproex vs 15.9 weeks with lithium plus placebo (not significant); relapse 53% vs 56% (Kemp et al., J Clin Psychiatry 2009). (missed)

Result source: NCT00194129

Divalproex sodium (Depakote ER)

Marketed by AbbVie

Approved in Bipolar Disordersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Bipolar Disorder

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Divalproex sodium (Depakote): registry results are on file for Bipolar Disorder, but their comparison mappings are not yet available.

Divalproex sodium (Depakote ER): registry results are on file for Bipolar Disorder, but their comparison mappings are not yet available.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Divalproex sodium (Depakote)'s landscape · Divalproex sodium (Depakote ER)'s landscape